期刊文献+

骨生化指标在骨肿瘤中的临床应用进展 被引量:3

Clinical application progress of bone biochemical markers in bone tumors
原文传递
导出
摘要 骨肿瘤是起源于间充质细胞,发生于骨组织及其附属结构的一类良、恶性肿瘤的总称,骨肿瘤的发病率女性约为1.060/10万,男性约为1.112/10万,虽属少见的肿瘤类型,但对人体的危害大,特别是恶性肿瘤,目前疗效虽然提高,但仍不令人满意,发病趋势呈年轻,在骨科领域中占有重要地位[1]。正常的骨代谢是骨生成和骨吸收的动态平衡,这种平衡主要有骨组织中成骨细胞或破骨细胞维持,当这种平衡被打破时就会表现出各种骨疾病。骨生成和骨吸收异常伴随的生化指标及导致骨生成和骨吸收变化的相关因素均可作为骨肿瘤的生物标记。随着分子生物学技术的发展,有望通过检测骨肿瘤患者体内的生化指标变化达到早期诊断和治疗的目的。现在就骨组织生化指标在骨肿瘤患者诊治中的研究作一综述,以探讨他们的临床应用价值。 Bone tumors refer to benign and malignant tumors which originate from mesenchymal stem cells and occur in bone tissues and their accessory structures. The pathogenesis and etiology of bone tumors still remain unclear, and the diagnosis methods of bone tumors are stagnating now. X-ray, computed tomography ( CT ) and magnetic resonance imaging ( MRI ) are important in diagnosing and evaluating bone tumors, but they cannot detect the lesions until the bone destruction reaches a certain degree. Isotope bone scan can detect the microscopic lesions of bone, whereas it is too expensive and the speciifcity is poor, with high false positive rates. At present, the golden standard for the diagnosis of bone tumors is the histopathological examination of bone. However, it is dififcult to achieve early diagnosis, and it is likely to miss the best treatment period. Every disease is inevitably accompanied by molecular biological changes in the body. Biochemical markers can promptly detect the property changes of bone tumor cells, including unlimited proliferation, apoptosis, active neoangiogenesis, inifltrative growth, metastatic growth and so on. Therefore, it is of great signiifcance for the diagnosis of bone tumors to detect appropriate biochemical markers in the patients. The normal bone metabolism is maintained by the dynamic balance of bone resorption and bone formation. When bone tumors occur, the balance will be disturbed. The bone biochemical markers which relfect bone resorption and bone formation are sensitive indicators of early abnormal bone metabolism. Recently, a large number of studies have explored the significance of bone biochemical markers in patients with bone tumors. The functions of bone biochemical markers in patients with bone tumors mainly include making an early detection of microscopic tumor lesions to start early treatment ( diagnostic effects ), evaluating the effects ( therapeutic monitoring ), evaluating the prognosis and predicting the risk of relapse ( prognostic judgment ) and developing new drugs to block abnormal metabolic pathways of bone tumors to achieve the goal of treatment ( therapeutic effects ).
出处 《中国骨与关节杂志》 CAS 2014年第2期156-160,共5页 Chinese Journal of Bone and Joint
关键词 临床应用价值 骨生化指标 骨肿瘤 分子生物学技术 生化指标变化 恶性肿瘤 肿瘤患者 间充质细胞 Tumor markers,biological Bone neoplasms Osteogenesis Bone resorption Osteoblasts Osteoclasts Bone matrix
  • 相关文献

参考文献4

二级参考文献50

  • 1郜玉峰,李旭,谢琴秀,桂淑玉,汪渊,周青,李家斌,江晓平.骨桥蛋白和CD44v6在肝癌中的表达及意义[J].中华肝脏病杂志,2005,13(3):227-228. 被引量:16
  • 2Mundy G.R. Metastasis to bone: causes,consequences and therapeutic opportunities[J]. Nat Rev Cancer, 2002,2( 8 ): 584-593.
  • 3Blair JM,Zhou H,Seibel MJ,et al. Mechanisms of disease: roles of OPG, RANKL andRANK in the pathophysiology of skeletal metastasis [J]. Nat Clin Pract Oncol, 2006,3 ( 1 ):41-49.
  • 4Liao J, McCauley LK. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP) [J]. Cancer Metastasis Rev, 2006,25 ( 4 ):559-571.
  • 5Thompson E.W,Sung V,Lavigne M,et al. LCC15-MB:a vimentin-positive human breast cancer cell line from a femoral bone metastasis[J]. Clin Exp Metastasis, 1999,17 (3): 193-204.
  • 6Iguchi H,Katakami H,Ichinose Y,et al. A case of squamous cell lung carcinoma with high concentration of parathyroid hormone-related peptide in serum and pleural effusion presenting hypercalcemia[J]. Jpn J Cancer Res, 1993,84(4):419-424.
  • 7Richard V, Luchin A, Brena R.M, et al. Quantitative evaluation of alternative promoter usage and 3' splice variants for parathyroid hormone-related protein byreal-time reverse transcription-PCR[J]. Clin Chem, 2003,49 ( 8 ):1398-1402.
  • 8LeRoy.B.E,Sellers.R.S,Rosol.T.J.Canine prostate stimulates osteoblast function using the endothelin receptors[J]. Prostate, 2004,59 (2): 148-156.
  • 9Guise TA,Yin JJ,Taylor SD,et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis[J]. Clin Invest, 1996,98:1544-1549.
  • 10Okoumassoun L,Averill-Bates D,Denizeau F,et al. Parathyroid hormone related protein(PTHrP) inhibits TNFalpha-induced apoptosis by blocking the extrinsic and intrinsic pathways.[J]. J Cell Physiol, 2007,210 (2):507-516.

共引文献30

同被引文献25

  • 1付立平,包迎伟,巫智强,叶月霞,龚向阳.成年人骨肉瘤的临床及影像学特点(附33例分析)[J].放射学实践,2007,22(3):282-285. 被引量:7
  • 2Aoun F, Peltier A, van-Velthoven R. A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer[J]. Biomed Res Int, 2014, 2014: 501213. DOI:10.1155/2014/501213.
  • 3Heidenreich A, Bastian P J, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65(1): 124-137. DOI:10.1016/j.eururo.2013.09.046.
  • 4Zacho H D, Manresa J A, Mortensen J C, et al. Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer[J]. Nucl Med Commun, 2015, 36(5): 445-451. DOI:10.1097/MNM.0000000000000279.
  • 5Lara P N Jr, Ely B, Quinn D I, et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421 [J]. J Natl Cancer Inst, 2014, 106(4): dju013. DOI:10.1093/jnci/dju013.
  • 6Kamiya N, Suzuki H, Endo T, et al. Clinical usefulness of bone markers in prostate cancer with bone metastasis[J]. Int J Urol, 2012, 19(11): 968-979. DOI:10.1111/j.1442-2042.2012.03098.x.
  • 7Zafeirakis A. Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer[J]. Hippokratia, 2010, 14(3): 164-169.
  • 8刘兴明,林丁,刘预,吴立翔,田明,林一民,黄学梅,易琳,杨静梅,张达容.羊Ⅰ型前胶原的提取、纯化与抗血清的制备应用于放免法的建立[J].重庆医学,2008,37(11):1203-1204. 被引量:1
  • 9杨欢,王波,周惠琴,谢小芳,温会燕,朱雪明.前列腺癌骨转移患者血清ICTP、PINP的表达及临床价值[J].临床输血与检验,2010,2(2):128-131. 被引量:5
  • 10杨勇昆(译),牛晓辉(校).骨肉瘤诊断、治疗、随访的ESMO临床指南[J].中国骨肿瘤骨病,2010(2):110-111. 被引量:14

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部